NeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% – Should You Sell?

NeuroPace, Inc. (NASDAQ:NPCE) dropped 4.3% on Friday . The company traded as low as $11.78 and last traded at $11.85. Approximately 168,073 shares changed hands during mid-day trading, an increase of 30% from the average daily volume of 128,856 shares. The stock had previously closed at $12.38.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Cantor Fitzgerald increased their price objective on NeuroPace from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. UBS Group assumed coverage on NeuroPace in a research report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 target price on the stock. Wells Fargo & Company lifted their price target on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, January 30th. Finally, JPMorgan Chase & Co. increased their price objective on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.20.

NeuroPace Trading Down 4.3 %

The company has a fifty day simple moving average of $12.63 and a two-hundred day simple moving average of $10.23. The company has a market capitalization of $385.84 million, a P/E ratio of -11.85 and a beta of 2.06. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. The business had revenue of $21.47 million for the quarter, compared to the consensus estimate of $21.14 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. On average, analysts forecast that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Ltd. Kck sold 5,270,845 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Martha Morrell sold 78,334 shares of NeuroPace stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $13.72, for a total value of $1,074,742.48. Following the completion of the transaction, the insider now directly owns 81,993 shares in the company, valued at approximately $1,124,943.96. This represents a 48.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,352,479 shares of company stock worth $50,670,217 in the last quarter. 22.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On NeuroPace

Several large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new position in shares of NeuroPace in the 4th quarter valued at $29,000. Wells Fargo & Company MN boosted its position in NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after buying an additional 2,279 shares in the last quarter. JPMorgan Chase & Co. grew its stake in NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after buying an additional 6,181 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of NeuroPace during the fourth quarter worth approximately $103,000. Finally, Birchview Capital LP bought a new position in shares of NeuroPace in the fourth quarter valued at approximately $112,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.